Japan Multi-Cancer Early Detection Testing Market Expands at 16.5% CAGR as Liquid Biopsy and AI-Driven Genomics Transform Early Cancer Screening

Leander, Texas and Tokyo, Japan - Jan.12.2026
As per DataM Intelligence research report "The global multi cancer early detection testing market reached US$ 1.67 billion in 2023, with a rise of US$ 1.92 billion in 2024, and is expected to reach US$ 7.52 billion by 2033, growing at a CAGR of 16.5% from 2025 to 2033." Rising global cancer prevalence, demand for non-invasive liquid biopsy technologies, advancements in genomics, AI-driven bioinformatics, next-generation sequencing, and supportive clinical studies are fueling growth in the multi cancer early detection testing market.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/multi-cancer-early-detection-testing-market?sindhuri

Japan: Recent Industry Developments
✅ In 2025, Japanese oncology centers and research institutions advanced adoption of liquid biopsy-based MCED approaches, integrating AI and genomic analysis for high-risk screening in aging populations.
✅ In 2025, Collaborations with global players like Guardant Health expanded access to methylation-based multi-cancer tests, aligning with Japan's focus on precision oncology and early intervention.
✅ In 2025, Government-backed initiatives promoted multi-cancer screening pilots, emphasizing non-invasive solutions amid rising incidence of lung, colorectal, and breast cancers.

United States: Recent Industry Developments
✅ In September 2025, Exact Sciences launched CancerguardTM, a first-of-its-kind multi-cancer early detection blood test analyzing multiple biomarker classes, available as an LDT nationwide through Quest Diagnostics.
✅ In June 2025, Guardant Health received FDA Breakthrough Device designation for its Shield multi-cancer detection test (methylation-based) for average-risk individuals aged 45+.
✅ In July 2025, Fred Hutch Cancer Center launched the Vanguard Study, a national evaluation of multi-cancer detection blood tests for early screening in ages 45-75.

Multi Cancer Early Detection Testing Market: Drivers
The multi cancer early detection testing market is driven by escalating global cancer burden (20 million new cases and 9.7 million deaths annually), limitations of traditional single-cancer screening, and demand for non-invasive, accurate alternatives like liquid biopsies. Technological progress in cfDNA methylation, next-generation sequencing, AI-powered analysis, and multi-biomarker approaches enable detection of multiple cancers from a single blood draw, improving early-stage identification and outcomes. Supportive regulatory designations, clinical validations, real-world evidence studies, and investments in precision oncology further accelerate adoption amid preventive healthcare priorities.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/multi-cancer-early-detection-testing-market?sindhuri

Multi Cancer Early Detection Testing Market: Major Players
GRAIL (Galleri), Guardant Health, Exact Sciences (Cancerguard/CancerSEEK), Burning Rock Biotech, Lucence Health, Foundation Medicine (Roche), AnchorDx, Freenome, Niramai.

Segment Covered in the Multi Cancer Early Detection Testing Market:
By Test Type
Galleri Test (dominant with ~40.66% share), CancerSEEK, Others.
By Cancer Type
Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Prostate Cancer, Others.
By End User
Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes.

Regional Analysis
North America - Dominant Share
North America holds 42.1% market share in 2024, driven by high cancer prevalence, advanced infrastructure, R&D investments, reimbursement support, and presence of leaders like GRAIL, Exact Sciences, and Guardant Health.
Asia Pacific - Fastest-Growing
Asia Pacific expands rapidly due to rising cancer incidence, improving diagnostics, healthcare investments, and adoption of innovative liquid biopsy technologies in emerging economies.
Europe - Significant Share
Europe grows with focus on precision medicine and regulatory support for novel diagnostics.
South America - Gradual Growth
South America shows steady progress amid increasing awareness and healthcare enhancements.
Middle East & Africa - Emerging Growth
Middle East & Africa rises with investments in oncology and growing demand for early detection.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=multi-cancer-early-detection-testing-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.